Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Patrick_Holt
|
| gptkbp:countryOfOrigin |
gptkb:Ireland
|
| gptkbp:focusesOn |
gptkb:cardiovascular_disease
|
| gptkbp:founded |
1993
|
| gptkbp:headquartersLocation |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Amarin Corporation plc
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:ISIN |
IE00B1GTXM62
|
| gptkbp:keyPerson |
gptkb:Patrick_Holt
gptkb:Aaron_Berg gptkb:Joseph_Kennedy gptkb:Thomas_Reilly Steven Ketchum |
| gptkbp:legalForm |
gptkb:public_company
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:market |
gptkb:Canada
gptkb:Europe gptkb:United_States |
| gptkbp:notableProduct |
gptkb:Vascepa
|
| gptkbp:numberOfEmployees |
~700
|
| gptkbp:product |
gptkb:Vascepa
|
| gptkbp:researchInterest |
omega-3 fatty acids
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:AMRN
|
| gptkbp:subsidiary |
Amarin Pharma, Inc.
|
| gptkbp:tradedOn |
NASDAQ: AMRN
|
| gptkbp:website |
https://www.amarincorp.com/
|
| gptkbp:bfsParent |
gptkb:AMRN
|
| gptkbp:bfsLayer |
8
|